Titre : Hyperthyroïdie

Hyperthyroïdie : Questions médicales fréquentes

Termes MeSH sélectionnés :

Proprotein Convertase 9
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Hyperthyroïdie : Questions médicales les plus fréquentes", "headline": "Hyperthyroïdie : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Hyperthyroïdie : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-07", "dateModified": "2025-05-02", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Hyperthyroïdie" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Maladies de la thyroïde", "url": "https://questionsmedicales.fr/mesh/D013959", "about": { "@type": "MedicalCondition", "name": "Maladies de la thyroïde", "code": { "@type": "MedicalCode", "code": "D013959", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C19.874" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Thyréotoxicose", "alternateName": "Thyrotoxicosis", "url": "https://questionsmedicales.fr/mesh/D013971", "about": { "@type": "MedicalCondition", "name": "Thyréotoxicose", "code": { "@type": "MedicalCode", "code": "D013971", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C19.874.397.685" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Crise thyréotoxique", "alternateName": "Thyroid Crisis", "url": "https://questionsmedicales.fr/mesh/D013958", "about": { "@type": "MedicalCondition", "name": "Crise thyréotoxique", "code": { "@type": "MedicalCode", "code": "D013958", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C19.874.397.685.905" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Hyperthyroïdie", "alternateName": "Hyperthyroidism", "code": { "@type": "MedicalCode", "code": "D006980", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "M Trebillod", "url": "https://questionsmedicales.fr/author/M%20Trebillod", "affiliation": { "@type": "Organization", "name": "Service d'Endocrinologie, CHU Liège, Belgique." } }, { "@type": "Person", "name": "P Pétrossians", "url": "https://questionsmedicales.fr/author/P%20P%C3%A9trossians", "affiliation": { "@type": "Organization", "name": "Service d'Endocrinologie, CHU Liège, Belgique." } }, { "@type": "Person", "name": "Priya Vaidyanathan", "url": "https://questionsmedicales.fr/author/Priya%20Vaidyanathan", "affiliation": { "@type": "Organization", "name": "Department of Pediatric Endocrinology, Children's National Hospital, Washington, DC 20010, USA. Electronic address: pvaidyan@childrensnational.org." } }, { "@type": "Person", "name": "David L Panciera", "url": "https://questionsmedicales.fr/author/David%20L%20Panciera", "affiliation": { "@type": "Organization", "name": "Department of Small Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Blacksburg, Virginia, USA." } }, { "@type": "Person", "name": "Katie M Boes", "url": "https://questionsmedicales.fr/author/Katie%20M%20Boes", "affiliation": { "@type": "Organization", "name": "Department of Biomedical Sciences & Pathobiology, Virginia-Maryland College of Veterinary Medicine, Blacksburg, Virginia, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Relationship between Serum Proprotein Convertase Subtilisin/Kexin Type 9 Concentration and Prevalence of Coronary Artery Calcium in a Community-Based Sample of Japanese Men.", "datePublished": "2022-09-17", "url": "https://questionsmedicales.fr/article/36123046", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.5551/jat.63549" } }, { "@type": "ScholarlyArticle", "name": "Proprotein convertases regulate trafficking and maturation of key proteins within the secretory pathway.", "datePublished": "2022-11-18", "url": "https://questionsmedicales.fr/article/36707198", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/bs.apcsb.2022.10.001" } }, { "@type": "ScholarlyArticle", "name": "Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Associated with Disease Activity and Risk of Incident Cardiovascular Disease in Patients with Systemic Lupus Erythematosus.", "datePublished": "2023-05-06", "url": "https://questionsmedicales.fr/article/37148453", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10753-023-01821-6" } }, { "@type": "ScholarlyArticle", "name": "Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors.", "datePublished": "2023-03-03", "url": "https://questionsmedicales.fr/article/36980904", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/genes14030632" } }, { "@type": "ScholarlyArticle", "name": "Safety and Effectiveness of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor, in Patients With Familial or Non-Familial Hypercholesterolemia - A Post-Marketing Survey (J-POSSIBLE).", "datePublished": "2023-01-11", "url": "https://questionsmedicales.fr/article/36631082", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1253/circj.CJ-22-0445" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies endocriniennes", "item": "https://questionsmedicales.fr/mesh/D004700" }, { "@type": "ListItem", "position": 3, "name": "Maladies de la thyroïde", "item": "https://questionsmedicales.fr/mesh/D013959" }, { "@type": "ListItem", "position": 4, "name": "Hyperthyroïdie", "item": "https://questionsmedicales.fr/mesh/D006980" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Hyperthyroïdie - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Hyperthyroïdie", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Hyperthyroïdie", "description": "Comment diagnostiquer l'hyperthyroïdie ?\nQuels examens sont utilisés pour confirmer l'hyperthyroïdie ?\nQuels symptômes indiquent une hyperthyroïdie ?\nQuel rôle joue la TSH dans le diagnostic ?\nPeut-on diagnostiquer l'hyperthyroïdie par des symptômes seuls ?", "url": "https://questionsmedicales.fr/mesh/D006980?mesh_terms=Proprotein+Convertase+9&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Hyperthyroïdie", "description": "Quels sont les symptômes courants de l'hyperthyroïdie ?\nL'hyperthyroïdie cause-t-elle des problèmes de sommeil ?\nComment l'hyperthyroïdie affecte-t-elle le poids ?\nY a-t-il des symptômes oculaires associés ?\nL'hyperthyroïdie peut-elle causer des palpitations ?", "url": "https://questionsmedicales.fr/mesh/D006980?mesh_terms=Proprotein+Convertase+9&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Hyperthyroïdie", "description": "Peut-on prévenir l'hyperthyroïdie ?\nLes antécédents familiaux influencent-ils le risque ?\nLe stress peut-il déclencher l'hyperthyroïdie ?\nUne alimentation équilibrée aide-t-elle ?\nLes carences en iode sont-elles un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D006980?mesh_terms=Proprotein+Convertase+9&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Hyperthyroïdie", "description": "Quels traitements existent pour l'hyperthyroïdie ?\nComment fonctionnent les médicaments antithyroïdiens ?\nQuand est-ce que la chirurgie est nécessaire ?\nL'iode radioactif est-il un traitement efficace ?\nQuels effets secondaires peuvent avoir les traitements ?", "url": "https://questionsmedicales.fr/mesh/D006980?mesh_terms=Proprotein+Convertase+9&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Hyperthyroïdie", "description": "Quelles sont les complications de l'hyperthyroïdie ?\nL'hyperthyroïdie peut-elle causer des problèmes cardiaques ?\nQu'est-ce qu'une crise thyroïdienne ?\nComment l'hyperthyroïdie affecte-t-elle les os ?\nY a-t-il des risques de complications psychologiques ?", "url": "https://questionsmedicales.fr/mesh/D006980?mesh_terms=Proprotein+Convertase+9&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Hyperthyroïdie", "description": "Quels sont les principaux facteurs de risque ?\nLe sexe influence-t-il le risque d'hyperthyroïdie ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nL'âge joue-t-il un rôle dans le risque ?\nLes traitements antérieurs de la thyroïde augmentent-ils le risque ?", "url": "https://questionsmedicales.fr/mesh/D006980?mesh_terms=Proprotein+Convertase+9&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer l'hyperthyroïdie ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic se fait par des tests sanguins mesurant les niveaux de TSH et T4 libre." } }, { "@type": "Question", "name": "Quels examens sont utilisés pour confirmer l'hyperthyroïdie ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des scintigraphies thyroïdiennes et des échographies peuvent être réalisées." } }, { "@type": "Question", "name": "Quels symptômes indiquent une hyperthyroïdie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent perte de poids, nervosité, palpitations et insomnie." } }, { "@type": "Question", "name": "Quel rôle joue la TSH dans le diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Une TSH basse indique souvent une hyperthyroïdie, car la thyroïde est hyperactive." } }, { "@type": "Question", "name": "Peut-on diagnostiquer l'hyperthyroïdie par des symptômes seuls ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Non, les symptômes doivent être confirmés par des tests sanguins." } }, { "@type": "Question", "name": "Quels sont les symptômes courants de l'hyperthyroïdie ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fatigue, irritabilité, tremblements et transpiration excessive." } }, { "@type": "Question", "name": "L'hyperthyroïdie cause-t-elle des problèmes de sommeil ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut entraîner des insomnies et des troubles du sommeil." } }, { "@type": "Question", "name": "Comment l'hyperthyroïdie affecte-t-elle le poids ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elle provoque souvent une perte de poids malgré un appétit accru." } }, { "@type": "Question", "name": "Y a-t-il des symptômes oculaires associés ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des problèmes oculaires comme l'exophtalmie peuvent survenir." } }, { "@type": "Question", "name": "L'hyperthyroïdie peut-elle causer des palpitations ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les palpitations cardiaques sont un symptôme fréquent." } }, { "@type": "Question", "name": "Peut-on prévenir l'hyperthyroïdie ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode de prévention spécifique, mais un suivi médical régulier aide." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils le risque ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un historique familial de maladies thyroïdiennes augmente le risque." } }, { "@type": "Question", "name": "Le stress peut-il déclencher l'hyperthyroïdie ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Le stress peut aggraver les symptômes, mais n'est pas une cause directe." } }, { "@type": "Question", "name": "Une alimentation équilibrée aide-t-elle ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut soutenir la santé thyroïdienne, mais ne prévient pas l'hyperthyroïdie." } }, { "@type": "Question", "name": "Les carences en iode sont-elles un facteur de risque ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Non, l'excès d'iode est plus souvent lié à l'hyperthyroïdie que la carence." } }, { "@type": "Question", "name": "Quels traitements existent pour l'hyperthyroïdie ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent les médicaments antithyroïdiens, l'iode radioactif et la chirurgie." } }, { "@type": "Question", "name": "Comment fonctionnent les médicaments antithyroïdiens ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Ils inhibent la production d'hormones thyroïdiennes par la glande thyroïde." } }, { "@type": "Question", "name": "Quand est-ce que la chirurgie est nécessaire ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La chirurgie est envisagée si les autres traitements échouent ou en cas de goitre volumineux." } }, { "@type": "Question", "name": "L'iode radioactif est-il un traitement efficace ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est souvent utilisé pour détruire les cellules thyroïdiennes hyperactives." } }, { "@type": "Question", "name": "Quels effets secondaires peuvent avoir les traitements ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent des éruptions cutanées, des douleurs articulaires et des troubles hépatiques." } }, { "@type": "Question", "name": "Quelles sont les complications de l'hyperthyroïdie ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des problèmes cardiaques, l'ostéoporose et la crise thyroïdienne." } }, { "@type": "Question", "name": "L'hyperthyroïdie peut-elle causer des problèmes cardiaques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut entraîner des arythmies et une insuffisance cardiaque." } }, { "@type": "Question", "name": "Qu'est-ce qu'une crise thyroïdienne ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "C'est une urgence médicale avec une augmentation soudaine des hormones thyroïdiennes." } }, { "@type": "Question", "name": "Comment l'hyperthyroïdie affecte-t-elle les os ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut entraîner une diminution de la densité osseuse, augmentant le risque d'ostéoporose." } }, { "@type": "Question", "name": "Y a-t-il des risques de complications psychologiques ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'hyperthyroïdie peut provoquer anxiété et dépression chez certains patients." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, le sexe féminin, et des antécédents familiaux de maladies thyroïdiennes." } }, { "@type": "Question", "name": "Le sexe influence-t-il le risque d'hyperthyroïdie ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les femmes sont plus susceptibles de développer une hyperthyroïdie que les hommes." } }, { "@type": "Question", "name": "Les maladies auto-immunes sont-elles un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des maladies comme la maladie de Graves augmentent le risque d'hyperthyroïdie." } }, { "@type": "Question", "name": "L'âge joue-t-il un rôle dans le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque augmente avec l'âge, surtout chez les personnes de plus de 60 ans." } }, { "@type": "Question", "name": "Les traitements antérieurs de la thyroïde augmentent-ils le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des traitements comme la radiothérapie peuvent augmenter le risque d'hyperthyroïdie." } } ] } ] }

Sources (3557 au total)

Relationship between Serum Proprotein Convertase Subtilisin/Kexin Type 9 Concentration and Prevalence of Coronary Artery Calcium in a Community-Based Sample of Japanese Men.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising new target for reducing low-density lipoprotein cholesterol (LDL-C) and cardiovascular events in high-risk patients. However, the i... Community-dwelling Japanese men (n=622) aged 46-82 years without a history of cardiovascular disease and lipid-lowering medications were included. Serum PCSK9 concentration and CAC score were measured... The average age, LDL-C, and median serum PCSK9 concentration were 68 years, 122 mg/dL, and 240 ng/mL, respectively. After multivariable adjustment for traditional cardiovascular risk factors, no signi... A higher serum PCSK9 concentration was associated with a higher CAC prevalence in men aged <60 years, which was independent of traditional cardiovascular risk factors....

Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Associated with Disease Activity and Risk of Incident Cardiovascular Disease in Patients with Systemic Lupus Erythematosus.

To study the relationship of serum PCSK9 and disease activity and major adverse cardiovascular events (MACEs) in systemic lupus erythematosus (SLE). Consecutive patients who fulfilled ≥ 4 ACR criteria...

Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has an important function in the regulation of lipid metabolism. PCSK9 reduces hepatic low-density lipoprotein receptors, thereby increasing low-d...

Safety and Effectiveness of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor, in Patients With Familial or Non-Familial Hypercholesterolemia - A Post-Marketing Survey (J-POSSIBLE).

This study evaluated the safety and effectiveness of alirocumab in Japanese patients with familial hypercholesterolemia (FH) or non-FH in a real-world clinical setting.Methods and Results: This post-m... Alirocumab was well tolerated and showed effectiveness in Japanese patients with hypercholesterolemia in a real-world clinical setting....

How safe are proprotein convertase subtilisinekexin type 9 inhibitors in diabetes?

To examine the safety of proprotein convertase subtilisinekexin type 9 (PCSK9) inhibitors in patients with diabetes, specifically focusing on their impact on glucose metabolism.... Patients with diabetes often require intensified lipid-lowering therapy. PCSK9 inhibitors can reduce low-density lipoprotein cholesterol (LDL-C) concentrations by approximately 60%, and significantly ... Although the majority of patients with diabetes are undergoing background statin therapy, which may mask potential adverse effects of PCSK9 inhibitors on glycaemic control, current data suggest that t...

Predictors of functional and morphological arterial wall properties in coronary artery disease patients with increased lipoprotein (a) levels before and after treatment with proprotein convertase subtilisin-kexin type 9 inhibitors.

In addition to proatherogenic properties, lipoprotein (a) (Lp(a)) has also pro-inflammatory, antifibrinolytic and prothrombogenic features. The aim of the current study was to identify the predictors ... Seventy-six post-myocardial infarction patients with high Lp(a) levels were included in the study. Ultrasound measurements of flow-mediated dilation of brachial artery (FMD), carotid intima-media thic... In linear regression model FMD significantly correlated with age at first myocardial infarction (β = 0.689; p = 0.022), high-sensitivity C-reactive protein (β = -1.200; p = 0.009), vascular cell adhes... Our results suggest that age, systolic blood pressure, Lp(a) levels and other biochemical markers associated with Lp(a) are predictors of functional and morphological properties of the arterial vessel... The protocol for this study was registered with clinicaltrials.gov on November, 3 2020 under registration number NCT04613167....

Proprotein convertase subtilisin/kexin type 9 (PCSK9) and clinical outcomes in dialysis patients.

Proprotein convertase subtilisin/kexin type 9 (PCSK9), a factor accelerating the degradation of LDL receptors, was associated with a gender-dependent risk for cardiovascular (CV) events in the general... The study enrolled 1188 dialysis patients from the Prospective Registry of The Working Group of Epidemiology of Dialysis Region Calabria (PROGREDIRE) cohort. PCSK9 was measured by colorimetric enzyme-... During a median 2.9-year follow-up, out of 494 deaths, 278 were CV-related. In unadjusted analyses, PCSK9 levels correlated with increased all-cause (HR... PCSK9 levels are unrelated to all-cause mortality in haemodialysis patients but, like in studies of the general population, independently of other risk factors, entail a doubling in the risk of CV eve...